Meitheal Pharmaceuticals has expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. (HKF), to market and distribute three biosimilars in the U.S. The agreement covers biosimilars for oncology medications pegfilgrastim and filgrastim as well as follitropin alpha in the fertility space. This expansion allows the company to deliver cost-saving innovation to patients and the broader healthcare system.